CCS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Century Communities Inc (CCS) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive developments in new community launches and affordable housing initiatives, the recent financial performance shows significant declines in revenue, net income, and EPS. Additionally, technical indicators suggest a bearish trend, and analyst ratings are mixed with a recent downgrade. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investing in CCS is recommended until stronger financial and technical signals emerge.
The MACD is slightly positive and expanding, but RSI is neutral at 38.197. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. Key support is at 55.098, and resistance is at 58.826. The stock is trading near its pivot level of 56.962, suggesting limited momentum in either direction.
Century Communities has launched several new communities, including affordable housing projects in Arizona and Atlanta, which could attract first-time buyers and support long-term growth. The Federal Reserve's transition to a lower rate environment and demographic tailwinds from millennials are also favorable for the company.
Analysts have issued mixed ratings, with JPMorgan lowering its price target to $49 and maintaining an Underweight rating. Technical indicators show a bearish trend, and there is no significant insider or hedge fund activity to suggest strong buying interest.
In Q4 2025, revenue dropped to $1.23 billion (-3.13% YoY), net income fell to $35.96 million (-65% YoY), and EPS declined to $1.21 (-62.19% YoY). However, gross margin slightly improved to 22.92% (+0.48% YoY), indicating some operational efficiency.
Analyst ratings are mixed. JPMorgan downgraded the stock with a price target of $49, citing reduced estimates. B. Riley raised its price target to $75, highlighting clean inventory and margin recovery. Citizens initiated coverage with an Outperform rating and a $92 price target, citing undervaluation and demographic tailwinds.
